You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Mounjaro ® (tirzepatide) injection
2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
What is the effect of Mounjaro® (tirzepatide) on fasting serum glucose?
Tirzepatide treatment consistently improved fasting serum glucose in patients with type 2 diabetes.
See important safety information, including boxed warning, in the attached prescribing information.
Fasting Serum Glucose in the Tirzepatide Type 2 Diabetes Studies
Mounjaro (tirzepatide) is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes (T2D) for once-weekly, subcutaneous administration.1
Treatment with tirzepatide 5, 10, and 15 mg was associated with improved fasting serum glucose (FSG) compared with baseline in adults with type 2 diabetes (T2D) compared with placebo, semaglutide 1 mg injection, titrated insulin degludec, titrated insulin glargine, and titrated insulin lispro in SURPASS clinical study program (Summary of Fasting Serum Glucose in SURPASS Studies).2-7
Two statistical estimands, efficacy or treatment-regimen, were used to evaluate efficacy data from the phase 3 clinical trials of tirzepatide.2-7
In the SURPASS clinical trial program, the
- efficacy estimand evaluates the treatment effect prior to discontinuation of the study drug, and
- treatment-regimen estimand evaluates the treatment effect irrespective of adherence to the study drug.2-7
Differences in reported data may reflect the application of these estimands. This response presents data reflecting the efficacy estimand. For treatment-regimen estimand results, please refer to the manuscript cited and/or the US prescribing information, where applicable.1-7
FSG, mg/dLa | Tirzepatide 5 mg | Tirzepatide 10 mg | Tirzepatide 15 mg | Comparatorb | ||||
SURPASS-1 | ||||||||
FSG at baseline | 153.7±3.7 | 152.6±3.7 | 154.6±3.7 | 155.2±3.8 | ||||
FSG change from baseline | -43.6±3.4 | -45.9±3.5 | -49.3±3.6 | 12.9±4.0 | ||||
Difference vs placeboc | -56.5 (-66.8, -46.1)*** | -58.8 (-69.2, -48.4)*** | -62.1 (-72.7, -51.5)*** | -- | ||||
SURPASS-2 | ||||||||
FSG at baseline | 174.2±2.39 | 174.6±2.40 | 172.3±2.39 | 170.9±2.40 | ||||
FSG change from baseline | -56.0±1.57 | -61.6±1.60 | -63.4±1.59 | -48.6±1.58 | ||||
Difference vs semaglutided | -7.3 (-11.7, -3.0)** | -13.0 (-17.4, -8.6)*** | -14.7 (-19.1, -10.3)*** | -- | ||||
SURPASS-3 | ||||||||
FSG at baseline | 171.8±2.44 | 170.7±2.44 | 168.4±2.44 | 166.4±2.44 | ||||
FSG change from baseline | -48.2±1.82 | -54.8±1.86 | -59.2±1.85 | -55.7±1.81 | ||||
Difference vs insulin degludecd | 7.5 (2.4, 12.5)** | 0.8 (-4.3, 5.9) | -3.6 (-8.7, 1.5) | -- | ||||
SURPASS-4 | ||||||||
FSG at baseline | 172.3±2.81 | 175.7±2.84 | 174.2±2.78 | 168.7±1.62 | ||||
FSG change from baseline | -50.4±2.07 | -54.9±2.06 | -59.3±2.04 | -51.4±1.17 | ||||
Difference vs insulin glargined | 1.0 (-3.7, 5.7) | -3.6 (-8.2, 1.1) | -8.0 (-12.6, -3.4)*** | -- | ||||
SURPASS-5 | ||||||||
FSG at baseline | 162.2±4.81 | 162.9±4.79 | 160.4±4.75 | 164.4±4.75 | ||||
FSG change from baseline | -61.4±2.55 | -67.9±2.55 | -67.7±2.64 | -38.9±2.49 | ||||
Difference vs placeboc | -22.5 (-29.5, -15.4)*** | -29.0 (-36.0, -22.0)*** | -28.8 (-35.9, -21.6)*** | -- | ||||
SURPASS-6 | ||||||||
FSG at baseline | 163.4±3.61 | 155.6±3.65 | 156.4±3.67 | 156.0±2.13 | ||||
FSG change from baseline | -33.2±3.28 | -43.0±3.32 | -41.6±3.42 | -10.0±1.99 | ||||
Difference vs insulin lisprod | -23.2 (-30.8, -15.7)*** | -33.0 (-40.6, -25.4)*** | -31.6 (-39.3, -23.8)*** | -- | ||||
Abbreviations: FSG = fasting serum glucose; LSM = least squares mean; mITT = modified intention-to-treat; MMRM = mixed model repeated measures.
Efficacy estimand evaluates the treatment effect prior to discontinuation of the study drug without confounding effects of antihyperglycemic rescue therapy. Analyzed by MMRM using the mITT population (efficacy analysis set).
**p<.01, and ***p<.001 versus comparator.
aData are LSM±SE at baseline and change from baseline at endpoint and treatment differences are LSM (95% CI).
bComparator was placebo in SURPASS-1 and SURPASS-5 for 40 weeks. Comparator was semaglutide 1 mg once weekly in SURPASS-2 for 40 weeks. Comparator was titrated insulin degludec in SURPASS-3 for 52 weeks. Comparator was titrated insulin glargine in SURPASS-4 for 52 weeks. Comparator was titrated insulin lispro in SURPASS-6 for 52 weeks.
cTested for superiority, controlled for type 1 error.
dNot controlled for type 1 error.
Enclosed Prescribing Information
References
The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).
1Mounjaro [package insert]. Indianapolis, IN: Eli Lilly and Company; 2026.
2Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143-155. https://doi.org/10.1016/S0140-6736%2821%2901324-6
3Frías JP, Davies MJ, Rosenstock J, et al; SURPASS-2 Investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515. https://doi.org/10.1056/NEJMoa2107519
4Ludvik B, Giorgino F, Jódar E, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021;398(10300):583-598. https://doi.org/10.1016/S0140-6736(21)01443-4
5Del Prato S, Kahn SE, Pavo I, et al; SURPASS-4 Investigators. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398(10313):1811-1824. https://doi.org/10.1016/S0140-6736(21)02188-7
6Dahl D, Onishi Y, Norwood P, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022;327(6):534-545. https://doi.org/10.1001/jama.2022.0078
7Rosenstock J, Frías JP, Rodbard HW, et al. Tirzepatide vs insulin lispro added to basal insulin in type 2 diabetes: the SURPASS-6 randomized clinical trial. JAMA. 2023;330(17):1631-1640. https://doi.org/10.1001/jama.2023.20294
8Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review: May 27, 2026